PTGS2 and neoplasm: In vivo studies also highlighted the benefits of curcumin (74 mg/kg) and 5-FU (52 mg/kg) co-administration in slowing down the tumor growth via the reduced expression of NF-κB and COX-2, without causing any toxicity effects in other body parts of gastric cancer xenograft models [137].